Risultati della ricerca - Daniel A. Scott

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence di Erica Chilson, Daniel A. Scott, Beate Schmoele-Thoma, Wendy Watson, Mary M. Moran, Raul Isturiz

Connect to this object online.

Late onset of injection site reactions after vaccination with the 13-valent pneumococcal conjugate vaccine in adult study populations di Christine Juergens, James Trammel, Yasuko Shoji, Scott Patterson, Wendy Watson, Chris Webber, William C. Gruber, Daniel A. Scott, Beate Schmoele-Thoma

Connect to this object online.

Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age di Raul E. Isturiz, Cassandra Hall-Murray, John M. McLaughlin, Vincenza Snow, Beate Schmoele-Thoma, Chris Webber, Allison Thompson, Daniel A Scott

Connect to this object online.

Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults di Beate Schmoele-Thoma, Martin van Cleeff, Richard N. Greenberg, Alejandra Gurtman, Thomas R. Jones, Vani Sundaraiyer, William C. Gruber, Daniel A. Scott

Connect to this object online.

A randomized phase 1 study of the safety and immunogenicity of 2 novel pneumococcal conjugate vaccines in healthy Japanese adults in the United States di David Fitz-Patrick, Mariano Young Jr, Daniel A. Scott, Ingrid L. Scully, Gary Baugher, Yahong Peng, Kathrin U. Jansen, William Gruber, Wendy Watson

Connect to this object online.

A randomized phase 1/2 study of the safety and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy adults 50 through 85 years of age di Brandon Essink, James Peterson, Kari Yacisin, Himal Lal, Sarah Mirza, Xia Xu, Ingrid L. Scully, Daniel A. Scott, William C. Gruber, Kathrin U. Jansen, Wendy Watson

Connect to this object online.

Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease di Charu Sabharwal, Vani Sundaraiyer, Yahong Peng, Lisa Moyer, Todd J. Belanger, Bradford D. Gessner, Luis Jodar, Kathrin U. Jansen, William C. Gruber, Daniel A. Scott, Wendy Watson

Connect to this object online.

A randomized, open-label, phase 3 study evaluating safety and immunogenicity of 13-valent pneumococcal conjugate vaccine in Chinese infants and children under 6 years of age di Kai Chu, Yuemei Hu, Hongxing Pan, Jingliang Wu, Dandan Zhu, Mariano M. Young, Li Luo, Zhuobiao Yi, Peter C. Giardina, William C. Gruber, Daniel A. Scott, Wendy Watson

Connect to this object online.

Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial di Bhagirath B. Solanki, Christine Juergens, Manojkumar B. Chopada, Pravin Supe, Vani Sundaraiyer, Natacha Le Dren-Narayanin, Mark W. Cutler, William C. Gruber, Daniel A. Scott, Beate Schmoele-Thoma

Connect to this object online.

Coadministration of 13-valent pneumococcal conjugate and quadrivalent inactivated influenza vaccines in adults previously immunized with polysaccharide pneumococcal vaccine 23: a r... di Allison R. Thompson, Nicola P. Klein, H. Jackson Downey, Scott Patterson, Vani Sundaraiyer, Wendy Watson, Keri Clarke, Kathrin U. Jansen, Shite Sebastian, William C. Gruber, Daniel A. Scott, Beate Schmöele-Thoma

Connect to this object online.

Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trial di Michael W. Simon, Regine Bataille, Nicole S. Caldwell, Bradford D. Gessner, Luis Jodar, Erik Lamberth, Yahong Peng, Daniel A. Scott, Lanyu Lei, Peter C. Giardina, William C. Gruber, Kathrin U. Jansen, Allison Thompson, Wendy Watson

Connect to this object online.